Please login to the form below

Not currently logged in
Email:
Password:

Ninlaro

This page shows the latest Ninlaro news and features for those working in and with pharma, biotech and healthcare.

Takeda can't sway NICE on oral myeloma therapy Ninlaro

Takeda can't sway NICE on oral myeloma therapy Ninlaro

Takeda can't sway NICE on oral myeloma therapy Ninlaro. Drug not recommended for NHS use in England and Wales. ... Ninlaro was approved by the EMA last November, becoming the first orally-active proteasome inhibitor to be registered in Europe.

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics